ERBB2 and breast carcinoma: For example, patients with HR+/HER2- advanced breast cancer and a high score in the ctDNA-based RB-LOH signature could be randomized to a chemotherapy-based treatment strategy versus the standard-of-care of endocrine therapy and CDK4/6 inhibition.